Inicio / Oncología / Abstracts de oncología / Expanding the Role for…

Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer

0 / 5 (0 votos)
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer

Cancer Cell

Fecha de publicación: 11 May 2020

DOI: https://doi.org/10.1016/j.ccell.2020.04.007

Autores: Peter Savas, Sherene Loi

Background: PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.